Get the Stockscreener App
2.35
4.47%
-0.11
After Hours:
2.35
Prokidney Corp stock is traded at $2.35, with a volume of 452.12K.
It is down -4.47% in the last 24 hours and up +35.84% over the past month.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$2.46
Open:
$2.46
24h Volume:
452.12K
Relative Volume:
0.45
Market Cap:
$332.63M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-4.1228
EPS:
-0.57
Net Cash Flow:
$-124.27M
1W Performance:
+5.38%
1M Performance:
+35.84%
6M Performance:
+4.44%
1Y Performance:
+125.96%
1-Day Range:
$2.32
$2.50
1-Week Range:
$2.15
$2.545
52-Week Range:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
2.35 | 348.20M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | H.C. Wainwright | Buy |
| Jun-30-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
ProKidney (NASDAQ:PROK) Stock Price Up 9%Here's Why - MarketBeat
PROKIDNEY CORP. (PROK) CFO awarded 600,000-share stock option grant - Stock Titan
ProKidney (NASDAQ: PROK) awards 400,000 stock options to Chief Regulatory Officer - Stock Titan
ProKidney (PROK) grants CLO Todd Girolamo 600,000 stock options - Stock Titan
ProKidney (NASDAQ: PROK) CEO awarded stock options on 3,000,000 shares - Stock Titan
PROK Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PROK Should I Buy - Intellectia AI
ProKidney Corp. (NASDAQ:PROK) Given Average Rating of "Hold" by Analysts - MarketBeat
Forecast Cut: Is ProKidney Corp impacted by rising ratesPortfolio Update Report & Verified Short-Term Plans - baoquankhu1.vn
Moving Averages: Should value investors consider ProKidney CorpJuly 2025 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
How ProKidney Corp. stock reacts to job market dataGDP Growth & Technical Pattern Based Signals - mfd.ru
CEO Change: Whats the outlook for ProKidney Corps sectorJuly 2025 Analyst Calls & Intraday High Probability Alerts - baoquankhu1.vn
What’s the outlook for ProKidney Corp.’s sectorWeekly Risk Report & Fast Gain Swing Alerts - mfd.ru
ProKidney Corp (PROK) Touts Reparencel Therapy for Growth - MSN
Why is ProKidney Corp. stock going downWeekly Stock Recap & Intraday High Probability Alerts - mfd.ru
Can ProKidney Corp. continue delivering strong returnsJuly 2025 Earnings & Verified Chart Pattern Signals - mfd.ru
Morgan Stanley discloses 6% ProKidney (PROK) stake in Schedule 13G - Stock Titan
3 Promising Penny Stocks With At Least $600M Market Cap - simplywall.st
Will ProKidney Corp. benefit from seasonalityMarket Activity Summary & High Conviction Trade Alerts - mfd.ru
Can ProKidney Corp. be the next market leader2025 Earnings Impact & Advanced Swing Trade Entry Alerts - mfd.ru
Will ProKidney Corp. benefit from green energy policiesWeekly Trading Summary & Reliable Breakout Stock Forecasts - mfd.ru
Is ProKidney Corp. stock a top performer YTDInflation Watch & Free Reliable Trade Execution Plans - mfd.ru
Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation - 富途牛牛
Revenue Check: Will ProKidney Corp benefit from geopolitical trendsBreakout Watch & Weekly High Return Forecasts - baoquankhu1.vn
Will ProKidney Corp. stock keep outperforming rivalsJuly 2025 Price Swings & Fast Moving Market Watchlists - mfd.ru
ProKidney Corp Explodes Into the Spotlight: Breakthrough Stock or Overhyped Trap? - AD HOC NEWS
Layoff Watch: Does ProKidney Corp offer margin of safety2025 Buyback Activity & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
HC Wainwright Forecasts ProKidney FY2030 Earnings - MarketBeat
Growth Value: Will CVCO benefit from sector rotationJuly 2025 WrapUp & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Is ProKidney Corp stock undervalued right nowMarket Growth Review & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
ProKidney Shares Soar After Citi Lifts Price Target to $9 - MSN
ProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating - TipRanks
ProKidney Expands Phase 3 REGEN-006 Trial Enrollment Plans - TipRanks
ProKidney CorpTopline data readout of surrogate endpoint expected Q2 2027 - marketscreener.com
Prokidney CorpTopline Data Readout Of Surrogate Endpoint Expected Q2 2027 - TradingView
ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK) - Seeking Alpha
ProKidney Corp. (NASDAQ:PROK) Receives Average Rating of "Hold" from Analysts - MarketBeat
Macro Review: Can CBTJ expand its profit margins2025 Volatility Report & Consistent Growth Equity Picks - baoquankhu1.vn
Aug Action: Can ProKidney Corp be the next market leaderTreasury Yields & Stock Portfolio Risk Management - baoquankhu1.vn
Ideas Watch: Should I buy ProKidney Corp stock nowTrade Performance Summary & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Profit Review: Does ProKidney Corp outperform in volatile marketsTrade Entry Report & Technical Entry and Exit Alerts - baoquankhu1.vn
Investment Review: Does ProKidney Corp offer margin of safety2025 Support & Resistance & Risk Controlled Daily Trade Plans - baoquankhu1.vn
PROKProKidney Latest Stock News & Market Updates - Stock Titan
ProKidney (NASDAQ:PROK) Stock Price Down 5.5%What's Next? - MarketBeat
Risk Recap: Why is ProKidney Corp stock going downPortfolio Update Report & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Bear Alert: Why is ProKidney Corp stock going downCPI Data & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
H.C. Wainwright Maintains ProKidney(PROK.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
PROK: Pivotal phase III trial of rilparencel for advanced CKD targets Q2 2027 readout, with strong phase II results - TradingView
Recap Report: What is the cash position of ProKidney CorpBuy Signal & Free High Return Stock Watch Alerts - baoquankhu1.vn
ProKidney Advances Rilparencel Program and Manufacturing Expansion - TipRanks
ProKidney Corp Updates on Rilparencel and Phase 3 Trials - TradingView
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):